Ferrante Dismisses Common Telemedicine-Cost Perceptions, Summarizes Senators’ Legislative Strategies
October 30, 2017
MedPage Today
Attorney TJ Ferrante was quoted in a MedPage Today article, “Telehealth Advocates Push for Expanded Use,” discussing why the perception that telemedicine will raise Medicare costs is inaccurate, and explaining why senators are floating multiple telemedicine bills – rather than just one – around Congress.
On the high-costs perception, Ferrante explained: “In 2016, Medicare spent about $28.7 million on telehealth services, and that might be a big number, but when it’s put into perspective, the overall Medicare budget is about $600-plus billion, so that’s an infinitesimal drop in the bucket … A lot of the concern that telehealth is going to cause costs [to skyrocket] isn’t based in reality.”
In conversation about the multiple bills floating around Congress, including the CONNECT Act and the CHRONIC Care Act, Ferrante said, “I think the approach this year is that they weren’t sure if one bill with all these bells and whistles was going to pass, so let’s have five, six or seven different pieces of legislation [that might get attached to bigger bills].”
On the high-costs perception, Ferrante explained: “In 2016, Medicare spent about $28.7 million on telehealth services, and that might be a big number, but when it’s put into perspective, the overall Medicare budget is about $600-plus billion, so that’s an infinitesimal drop in the bucket … A lot of the concern that telehealth is going to cause costs [to skyrocket] isn’t based in reality.”
In conversation about the multiple bills floating around Congress, including the CONNECT Act and the CHRONIC Care Act, Ferrante said, “I think the approach this year is that they weren’t sure if one bill with all these bells and whistles was going to pass, so let’s have five, six or seven different pieces of legislation [that might get attached to bigger bills].”
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."